What's Going On With Cardiff Oncology Stock On Tuesday? [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC) The CRDF-004 phase 2 trial is currently enrolling patients with mCRC who have a documented KRAS or NRAS mutation Onvansertib is added to SoC consisting of FOLFIRI plus bevacizumab or FOLFOX plus bevacizumab. Patients are being randomized in a 1:1:1 ratio to either 20mg of onvansertib plus SoC, 30mg of onvansertib plus SoC, or SoC alone. Efficacy and safety data are for all evaluable patients as of November 26. An objective response rate of 57% was observed in all onvansertib patients, with 50% in the 20mg dose of onvansertib + SoC arm and 64% in the 30mg dose of onvansertib + SoC arm, compared to 33% in the SoC alone arm. Spider Plots, displaying the change in tumor size from baseline for each patient over time, demonstrate deeper responses observed in patients receiving the 30mg dose of onvansertib combined with the SoC compared to the control arms and 20mg dose of onvans
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Cardiff Oncology, Inc. (NASDAQ: CRDF) had its price target raised by analysts at Piper Sandler from $7.00 to $10.00. They now have an "overweight" rating on the stock.MarketBeat
- Cardiff Oncology announces positive colorectal data and $40m stock oversubscription [Yahoo! Finance]Yahoo! Finance
- Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More [Yahoo! Finance]Yahoo! Finance
- CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/7/24 - Beat
CRDF
Sec Filings
- 12/18/24 - Form 4
- 12/17/24 - Form SCHEDULE
- 12/16/24 - Form 4
- CRDF's page on the SEC website